Increasing underrepresentation of elderly patients with advanced colorectal or non‐small‐cell lung cancer in chemotherapy trials
Ross R. Jennens, Graham G. Giles, Richard M. Fox · Internal Medicine Journal · 2006
BACKGROUND: Elderly patients are underrepresented in chemotherapy trials for advanced colorectal cancer (CRC) and non-small-cell lung cancer (NSCLC). However, the change in underrepresentation over time has not been documented. AIMS: This study aimed to quantify (i) the change in the median age of patients enrolled in clinical trials for metastatic CRC and NSCLC between 1982-1991 and 1992-2001 compared with the general colorectal and lung cancer population, and (ii) the proportion of trials with an upper age limit for eligibility. METHODS: A retrospective review of data from the Victorian Cancer Registry and all large published randomized chemotherapy trials for advanced CRC and NSCLC between 1982 and 2001 was conducted. RESULTS: The median age of patients with CRC enrolled in clinical trials remained constant between the two decades (62.0 and 62.2 years), whereas the median age of the CRC population increased from 68.4 to 70.2 years, increasing the median age difference from 6.4 to 8.0 years. The median age of patients with lung cancer in clinical trials increased from 59.8 to 61.8 years, whereas the median age of the lung cancer population increased from 67.4 to 70.4 years, widening the age difference from 7.6 to 8.6 years. More trials set an upper age limit for eligibility in the first decade than in the second decade for both CRC (51 vs 29%, P = 0.04) and NSCLC (68 vs 41%, P = 0.03). CONCLUSION: International clinical trials for CRC and NSCLC are becoming increasingly unsuitable for application to Australian patients because of the increasing age discrepancy, despite fewer trials restricting eligibility by age.
Cited by 90 works. doi:10.1111/j.1445-5994.2006.01033.x
Authors
References
- Cancer Incidence in Five Continents
- Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
- Annual Report to the Nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden
- Cancer—Principles & Practice of Oncology
- Representation of older patients in cancer treatment trials
- Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer
- How Sociodemographics, Presence of Oncology Specialists, and Hospital Cancer Programs Affect Accrual to Cancer Treatment Trials
- Cancer burden in the aged: an epidemiologic and demographic overview.
- Cancer burden in the aged
- Effectiveness of Chemotherapy for Advanced Lung Cancer in the Elderly: Instrumental Variable and Propensity Analysis